Nicardipine

Nicardipine

Nicardipine
Systematic (IUPAC) name
2-[benzyl(methyl)amino]ethylmethyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Clinical data
Trade names Cardene
AHFS/Drugs.com
MedlinePlus
Legal status
  • (Prescription only)
Routes of
administration
Oral, intravenous
Pharmacokinetic data
Protein binding >95%
Biological half-life 8.6 hours
Identifiers
CAS Registry Number  Y
ATC code C08
PubChem CID:
IUPHAR/BPS
DrugBank  Y
ChemSpider  Y
UNII  Y
KEGG  Y
ChEMBL  Y
Chemical data
Formula C26H29N3O6
Molecular mass 479.525 g/mol
Physical data
Melting point 136–138 °C (277–280 °F)
 Y   

Nicardipine hydrochloride (Cardene) is a medication used to treat high blood pressure and angina. It belongs to the class of calcium channel blockers.

Nicardipine is a dihydropyridine calcium-channel blocking agent used for the treatment of vascular disorders such as chronic stable angina, hypertension, and Raynaud's phenomenon. It is available in oral and intravenous formulations. Its mechanism of action and clinical effects closely resemble those of nifedipine and the other dihydropyridines (amlodipine, felodipine), except that nicardipine is more selective for cerebral and coronary blood vessels. Furthermore, nicardipine does not intrinsically decrease myocardial contractility and may be useful in the management of congestive heart failure. Nicardipine also has a longer half-life than nifedipine. Nicardipine was approved by the FDA in December 1988. The patent for both Cardene and Cardene SR expired in October 1995.[1]

It has been used in percutaneous coronary intervention.[2]

References

  1. ^ Nicardipine at Medline PLus
  2. ^ Huang RI, Patel P, Walinsky P, et al. (November 2006). "Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention". Catheter Cardiovasc Interv 68 (5): 671–6.